These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 22257685

  • 1. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.
    Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB, Rich MW, Pitt B, White M, Bakris GC, Fonarow GC, Ahmed A.
    Int J Cardiol; 2013 Jul 15; 167(1):151-6. PubMed ID: 22257685
    [Abstract] [Full Text] [Related]

  • 2. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
    McCallum W, Tighiouart H, Ku E, Salem D, Sarnak MJ.
    Am J Kidney Dis; 2020 Jan 15; 75(1):21-29. PubMed ID: 31303349
    [Abstract] [Full Text] [Related]

  • 3. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J.
    Am Heart J; 1999 Nov 15; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.
    Circ Heart Fail; 2011 Jan 15; 4(1):18-26. PubMed ID: 21036889
    [Abstract] [Full Text] [Related]

  • 5. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
    Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW.
    Am J Med; 2012 Apr 15; 125(4):399-410. PubMed ID: 22321760
    [Abstract] [Full Text] [Related]

  • 6. [The new drug is much more effective than ACE inhibitors in chronic heart failure].
    Widimský J.
    Vnitr Lek; 2015 Feb 15; 61(2):129-33. PubMed ID: 25813256
    [Abstract] [Full Text] [Related]

  • 7. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 8. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment.
    Higuchi S, Kohsaka S, Shiraishi Y, Katsuki T, Nagatomo Y, Mizuno A, Sujino Y, Kohno T, Goda A, Yoshikawa T, West Tokyo Heart Failure (WET-HF) Registry Investigators.
    Eur J Intern Med; 2019 Apr 20; 62():58-66. PubMed ID: 30737061
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner DV, Dries DL, Domanski MJ, Cohn JN.
    N Engl J Med; 2001 May 03; 344(18):1351-7. PubMed ID: 11333991
    [Abstract] [Full Text] [Related]

  • 11. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
    Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D.
    Circulation; 1993 Nov 03; 88(5 Pt 1):2277-83. PubMed ID: 8222122
    [Abstract] [Full Text] [Related]

  • 12. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
    Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D.
    Circulation; 1992 Aug 03; 86(2):431-8. PubMed ID: 1638712
    [Abstract] [Full Text] [Related]

  • 13. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR.
    Cardiovasc Drugs Ther; 2008 Aug 03; 22(4):305-11. PubMed ID: 18309461
    [Abstract] [Full Text] [Related]

  • 14. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
    Lam PH, Dooley DJ, Fonarow GC, Butler J, Bhatt DL, Filippatos GS, Deedwania P, Forman DE, White M, Fletcher RD, Arundel C, Blackman MR, Adamopoulos C, Kanonidis IE, Aban IB, Patel K, Aronow WS, Allman RM, Anker SD, Pitt B, Ahmed A.
    Eur J Heart Fail; 2018 Feb 03; 20(2):359-369. PubMed ID: 28980368
    [Abstract] [Full Text] [Related]

  • 15. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S.
    Eur J Heart Fail; 2014 Mar 03; 16(3):325-33. PubMed ID: 24464788
    [Abstract] [Full Text] [Related]

  • 16. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
    Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA.
    J Am Coll Cardiol; 1998 Feb 03; 31(2):419-25. PubMed ID: 9462588
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J, ATMOSPHERE Investigators.
    Eur J Heart Fail; 2011 Jan 03; 13(1):107-14. PubMed ID: 21169387
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S.
    Indian Heart J; 2020 Jan 03; 72(6):535-540. PubMed ID: 33357641
    [Abstract] [Full Text] [Related]

  • 20. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M.
    Circ Heart Fail; 2016 Jun 03; 9(6):. PubMed ID: 27296397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.